Adjunctive hormones — DHEA and melatonin

The premise

DHEA and melatonin are framed as "adjunctive" hormones in most teaching materials — the two you reach for after the headliners (estrogen, progesterone, testosterone, thyroid) are already optimized. The framing is convenient but it understates both molecules. DHEA is an upstream precursor: the adrenal gland synthesizes it, and downstream tissues use it to produce estrogens and androgens locally. Levels fall predictably with age, fall further under chronic inflammatory load (SLE, RA), and fall further still under cortisol-dominant chronic stress. Melatonin is even less well-served by the "sleep hormone" label most patients arrive with — its receptors live in brain, retina, liver, gut, kidney, vascular endothelium, adipocytes, immune cells, and reproductive organs, and the trial literature reads more like an oncology / cardiovascular / circadian adjuvant than a sleep aid.

Two things make this module its own beast. First, the formulation rule inverts. The SR-only-or-never rule that applied to thyroid and progesterone (where SR is contraindicated) reverses for DHEA and melatonin (where SR is required). Second, each molecule carries an absolute contraindication that gates initiation: pregnancy / breastfeeding for DHEA (teratogenic), and active immunosuppressant therapy for melatonin (immune-upregulating). Miss either and the rest of the protocol does not matter.

Pre-test

DHEA physiology — the upstream precursor

DHEA is produced in the zona reticularis of the adrenal cortex and converted in peripheral tissue to androstenedione and onward to testosterone and estrogens via the steroidogenic pathway. The sulfated form, DHEA-S, dominates the circulating pool — it is the stable reservoir most laboratories report. DHEA-S declines roughly linearly with age starting in the third decade and is suppressed further by chronic cortisol elevation (the "adrenal shunt" framing taught in functional endocrinology), by chronic inflammatory disease (SLE, RA), and by glucocorticoid therapy.

The pharmacology argument for replacement is essentially substrate logic: tissues that need local estrogen or androgen synthesis (skin, bone, vagina, brain) cannot make it if the upstream precursor pool has collapsed. That logic carries the trial evidence furthest in women with SLE / RA, where DHEA replacement has reproducible signal on disease activity and symptom control. ^{[Petri-SLE-DHEA]} The argument generalizes less cleanly outside autoimmune disease, which is why the Nimbus protocol leans on age-band thresholds rather than a single universal recommendation.

DHEA dose bands — by sex, weight, age, and autoimmune indication

The Nimbus dose bands replace the conventional "10–50 mg QAM" sliding-scale dosing with discrete bands keyed to physiology. SR compounded capsules are the only formulation Nimbus prescribes.

Androgenic adverse events (acne, hirsutism, scalp-hair thinning) are the dose-limiting toxicity in women. The clinical response is to drop dose, switch to every-other-day dosing, or — if a confirmed androgenic AE persists in a female patient — add spironolactone (maximum 100 mg BID). Spironolactone is ineffective for the analogous AE pattern in male patients and should not be added there.

DHEA-S targets — and why the lab is DHEA-S, not DHEA

Optimal serum targets are 500–600 mcg/dL in men and 200–250 mcg/dL in women. Both are off-label biochemical targets — the FDA has not approved DHEA replacement to a serum endpoint — but they are the Nimbus protocol because they correlate with the symptom-relief endpoints (energy, mood, libido, exercise tolerance) that drive the clinical decision. Recheck at 8–12 weeks after initiation or any dose change.

The lab to order is DHEA-S, not DHEA. DHEA itself fluctuates widely with ACTH pulses and circadian rhythm; DHEA-S (the sulfate form) has a half-life of roughly 7–10 hours and gives a stable, vendor-reproducible reading from a single morning draw.

SR only — no 7-keto, no cream

Two formulation traps are common in retail and functional-medicine settings.

7-keto DHEA is a metabolite, not a precursor. It cannot re-enter the steroidogenic pathway as the parent molecule does. Substituting 7-keto for DHEA gives none of the downstream conversion to estrogens or androgens — patients pay for it and get nothing of the intended effect. Nimbus does not use 7-keto for any DHEA indication.

DHEA cream has poor cutaneous absorption, the suspension grits visibly on the skin, and serum levels are unreliable. The Nimbus formulation is SR oral capsule. Vaginal DHEA is the exception, where local action — not systemic — is the goal.

Vaginal DHEA — Intrarosa and compounded variants

Intrarosa 6.5 mg PV QHS is FDA-approved for moderate-to-severe dyspareunia in postmenopausal women. The mechanism is local conversion of DHEA to estrogen and testosterone in vaginal epithelium and submucosa — systemic absorption is minimal, which is why the labeled indication carries a different risk profile than systemic estrogen. Compounded vaginal DHEA formulations exist; their use is off-label but commonly indicated when a patient cannot tolerate or access Intrarosa.

Pre-40 women — avoid unless SLE / RA / CTD

Systemic DHEA is not a routine optimization tool in women under 40. Below that age, endogenous DHEA-S is typically intact, the symptomatic benefit window is narrower, and the androgenic AE rate (acne, hirsutism) is not outweighed by the gain. The exception is connective-tissue disease — SLE, RA, and adjacent autoimmune indications — where DHEA-S is often suppressed by chronic inflammation and glucocorticoid therapy and the trial signal supports a 25–50 mg SR dose.^{[Petri-SLE-DHEA]}

For low-DHEA-S workups in women under 40 without a CTD indication, work the upstream causes first: thyroid dysfunction, iron deficiency, sleep restriction, mood, oral contraceptive effects on adrenal output. DHEA replacement is a downstream tool.

Absolute contraindications — pregnancy and breastfeeding

DHEA is teratogenic. Pregnancy and breastfeeding are absolute contraindications, not relative. The block is hard in both directions: do not initiate in a patient who is pregnant, planning pregnancy, or breastfeeding, and discontinue immediately if pregnancy is confirmed on therapy. This is the highest-yield contraindication to memorize because the OTC supplement framing of DHEA leads patients to assume it is benign.

The clinical-decision-support checklist for any DHEA initiation:

1. Pregnancy test in any woman of reproductive potential.
2. Breastfeeding status confirmed.
3. Active or historical hormone-sensitive cancer (breast, prostate, endometrial) triaged with oncology before initiation.
4. Age and CTD status confirmed to pick the dose band.
5. DHEA-S baseline drawn, not serum DHEA.

Mid-module checkpoint — the SR rule reversal

Melatonin physiology — pineal, dim-light, and age-related decline

Melatonin is synthesized primarily in the pineal gland from serotonin in a dim-light-gated rhythm (the suprachiasmatic nucleus is the master clock; light exposure suppresses synthesis). Peripheral synthesis also occurs in the GI tract, skin, bone marrow, and lymphocytes — melatonin is therefore not solely a circadian-rhythm molecule. Receptor sites span brain, retina, liver, intestine, kidney, gallbladder, the cardiovascular endothelium, immune cells, adipocytes, and reproductive organs, which sets up the pleiotropic clinical profile.

Endogenous melatonin secretion declines with age, with screen / artificial-light exposure, and with shift work. Patients on the Nimbus protocol who present with insomnia, maladapted shift schedules, jet lag, REM-disturbed sleep, or nocturia in Parkinson's disease are candidates for replacement — within the boundary set by the immunosuppressant contraindication below.

Melatonin dosing — start low, titrate to clinical effect

The standard Nimbus starting protocol:

• Women: 1–3 mg SR PO 1 hour before sleep.
• Men: 3 mg SR PO 1 hour before sleep.
• Sensitive patients: 0.5–1 mg SR.
• Women already on oral micronized progesterone: start at 1 mg SR (progesterone itself is sedating; stacking sedatives invites grogginess).
• Refractory insomnia: titrate up to 30 mg SR; rarely 100 mg SR for cancer-adjuvant or refractory indications.

Formulation is sustained-release. The clinical reason is the same as the physiologic reason — endogenous melatonin rises gradually after dim-light onset and remains elevated for several hours; IR melatonin produces a peak-and-crash profile that mismatches the natural curve and produces more morning grogginess.

Melatonin clinical effects — beyond sleep

Jet lag. The Cochrane systematic review of melatonin for jet lag found melatonin taken close to the target-destination bedtime (typically 10 PM to midnight) reduced jet lag for flights crossing five or more time zones, with a number-needed-to-treat of 2.^{[Cochrane-Jetlag-2002]} Daily doses of 0.5–5 mg were similarly effective; doses above 5 mg conferred no further benefit. Eastward travel responds more strongly than westward. Timing matters more than dose: melatonin taken too early in the day causes daytime sleepiness and delays adaptation.

REM sleep normalization. Two RCTs by Kunz and colleagues showed melatonin can normalize REM-sleep percentage, continuity, and architecture, with measurable daytime well-being effects.^{[Kunz-REM-2004]} REM is qualitatively disturbed and quantitatively reduced by aging, brain disorders, and many psychotropic drugs — relevant for the postmenopausal and elderly patients who most commonly arrive at Nimbus.

Nocturia in Parkinson's disease. An open-label pilot of 2 mg SR melatonin in PD patients with nocturia showed significant improvement in nocturnal voiding frequency and volume.^{[Batla-2021-Nocturia]} The mechanism is reframed: nocturia in PD is increasingly viewed as circadian dysregulation rather than purely urological. TODO(citation): confirm exact Batla 2021 reference and trial register identifier before publication.

Oncostatic activity. Reiter and Lissoni groups have published extensively on melatonin's oncostatic mechanisms — direct ROS / RNS detoxification, antioxidant-enzyme stimulation, MT1 / MT2 receptor modulation of apoptosis, angiogenesis inhibition, and epigenetic modulation.^{[Reiter-Oncostatic][Lissoni-Oncology]} Documented oncostatic signal exists across breast, ovarian, prostate, oral, gastric, and colorectal cancers — including as an adjuvant that reinforces chemotherapy and radiation effect while reducing chemotoxicity. Melatonin is framed as a promising adjunct, not a substitute, for prevention or treatment, and oncology co-management is required in active treatment.

Nocturnal blood pressure. Daily nighttime melatonin in men with essential hypertension reduced blood pressure in a controlled trial by Scheer and colleagues — a finding consistent with the central / peripheral circadian regulation framework.^{[Scheer-BP-2004]}

Melatonin — the absolute contraindication on immunosuppressant therapy

Melatonin upregulates innate and cellular immunity: it stimulates progenitor cells, granulocytes, macrophages, NK cells, and increases IL-2, IL-6, IL-12, and T-helper / CD4+ counts.^{[Srinivasan-Immune-2005]} For a healthy patient that is the upside. For a patient on immunosuppressant therapy it is the contraindication: melatonin directly antagonizes the therapeutic goal of the suppressant.

Translate that to the patient list. Any of the following is an absolute block:

• Transplant patients on tacrolimus, cyclosporine, mycophenolate mofetil (MMF), sirolimus, or comparable agents.
• Autoimmune-disease patients on methotrexate, biologics (TNF-alpha inhibitors, IL-6 inhibitors, JAK inhibitors), or high-dose corticosteroids.
• Oncology patients on immunotherapy where immune suppression is part of the therapeutic plan — coordinate with oncology, never assume.

Nimbus-vs-mainstream — the framing summary

Adverse-event playbook

Two short ladders worth memorizing.

DHEA — androgenic AEs in women (acne, hirsutism, hairline thinning): reduce dose; switch to every-other-day; if confirmed AE persists, add spironolactone up to 100 mg BID. In men on combined T + DHEA, facial / hairline acne is frequently DHEA-driven rather than testosterone-driven — reduce DHEA before assuming T is the cause.

• Morning grogginess: shift dose to 2 hours before bed or with dinner; consider IR; reduce dose.
• Vivid dreams or nightmares: drop to a low starting dose and titrate up by 0.5 mg increments.
• Paradoxical insomnia: restart at a very low dose with slow titration.

Two short case studies

Case — a 45-year-old woman with chronic pain and low DHEA-S (first-name only: "Kate"). Baseline DHEA-S below the female target range. Started on DHEA SR. At follow-up, pain improved by an "8-out-of-10" patient-reported margin and SR dose was increased to 25 mg BID to optimize further. Other hormone deficiencies were sequenced afterward.

Case — a 58-year-old man with depression, low motivation, fatigue, and sleep disturbance ("Paul"). Baseline labs (Quest): TSH 1.32, FT4 0.99, FT3 4.4, DHEA-S 201 mcg/dL (low for the male target), Total cholesterol 198, HDL 30, TG 401, Total T 305 ng/dL, Free T 42 pg/mL, PSA 1.5. Plan: clear primary care first, start DHEA SR 50 mg daily, recheck at 8–12 weeks. At follow-up DHEA-S rose to 501 mcg/dL — in the male target range — and the patient's depression had improved per partner report. Testosterone replacement was discussed and deferred pending readiness.

Role-specific guidance

Post-test

Module evaluation